LRRK2 and Parkinson disease: In addition to successful differentiation of control iPSC lines into iMGL, the 2.9 protocol was also confirmed to allow the differentiation of Parkinson’s disease patient-derived lines harboring glucocerebrosidase (GBA) or leucine-rich repeat kinase 2 (LRRK2) pathogenic variants (Additional file 1: Figure S3A-B).